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INTRODUCTION:  Mucinous  cystic  neoplasms  (MCN)  are  uncommon  tumors  of the  pancreatic  corpus/tail
occurring  mostly  in  middle-aged  women,  with  a variable  clinico-biological  behavior.  On  histology,  MCNs
concurrently  show  an  epithelial  mucosecreting  component  with  ovarian-type  stromal  cells.
PRESENTATION OF  CASE:  This  report  describes  the ﬁrst case  of  a  pancreatic  MCN  with  no ovarian-type
stroma  in a patient  with  Turner  syndrome  (TS).eywords:
ancreatic mucinous cystic neoplasm
ystadenoma
ystadenocarcinoma
urner syndrome
DISCUSSION: The  mesenchymal  component  of MCN  presumably  results  from  the  intra-pancreatic  entrap-
ment  of  ovarian  stroma  during embryogenesis.  In  our case,  the  absence  of such  stromal  component  may
relate  to the “dysgenetic”  changes  in the  ovary  involved  in TS.
CONCLUSION: The  present  case  of primary  pancreatic  MCN  arising  in  a TS-patient  triggers  some  original
speculation  on  the  morphogenesis  of  pancreatic  MCN,  also  expanding  the  current  clinico-pathological
knowledge  of  this  extremely  rare  entity.
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. Introduction
Pancreatic cystic neoplasms include both benign and malig-
ant diseases. Within otherwise solid pancreatic tumors, cystic
hanges may  result from necrosis/hemorrhage due to the neo-
lasm’s growth (i.e. degenerative cysts).1 Among “natively” cystic
umors, the neoplastic cells’ phenotype distinguishes serous from
ucinous subtypes. Based on its epidemiological, clinical and
athological proﬁle, the mucinous subgroup is further divided into
ucinous cystic neoplasms (MCN) and intraductal papillary muci-
ous neoplasms (IPMN). A distinctive histological feature of MCN
s the coexistence of an epithelial mucosecreting component with
varian-type stroma (which is lacking in IPMN).1,2
Turner syndrome (TS) belongs to the spectrum of the “prema-
ure ovarian failures”, and is characterized by early ovarian demise
ith insufﬁcient circulating levels of female sex steroids.
Abbreviations: IPMN, intraductal papillary mucinous neoplasm; MCN, mucinous
ystic neoplasm; US, ultrasound echography; SPNP, solid-pseudopapillary neoplasm
f the pancreas; TS, Turner syndrome.
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This report describes the ﬁrst case of a primary pancreatic MCN
with no ovarian stroma, occurring in a TS patient.
2. Case report
In  September 2011, a 42-year-old Caucasian woman with TS
was referred to the Surgery Department of Padua Teaching Hos-
pital (Padua, Italy) with a cystic lesion (11 cm in size) of the tail
of the pancreas. The lesion had initially been identiﬁed when the
patient was  18 years old (an incidental ultrasound [US] ﬁnding),
when it had been diagnosed as an “adrenal cyst”. At the time of
this initial assessment, the lesion had been 4.5 cm in size and fea-
tured a well-deﬁned, thin wall and a homogeneous ﬂuid content.
Laboratory tests (including serum tumor markers) had revealed
nothing of signiﬁcance. Subsequent annual US follow-up showed
a gradual enlargement of the cyst, with newly appearing mural
nodules, and changes in the cyst’s contents (from ﬂuid to hemor-
rhagic/corpusculated). In 2007, a check-up revealed above-normal
CA19-9 levels (901.6 U/mL [normal range: 0–37 U/mL]), and sub-
sequent abdominal computed tomography deﬁnitively located the
lesion within the pancreatic tail (Fig. 1). Neither endoscopic US, nor
cytology of the cystic ﬂuid were performed. The patient refused
Open access under CC BY-NC-ND license.surgery until 2011, when a pancreatic tail resection with splenec-
tomy was  performed.
The  gross surgical specimen featured a single, rounded cyst with
a ﬁbrous (focally calciﬁed) pseudo-capsule. The cut surface dis-
closed a multi-locular cyst ﬁlled with hemorrhagic mucus; solid
mural nodules coexisted with intra-luminal protrusions (Fig. 2A).
s Ltd. Open access under CC BY-NC-ND license. 
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Fig. 1. Abdominal computed tomography (CT) of the pancreatic lesion. Contrast-
enhanced abdominal CT discloses a large, well-demarcated cyst of the pancreatic tail
displacing the stomach and spleen. The ﬂuid content is barely corpusculated. Note
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consisting of poorly cohesive monomorphic cells, admixed with
T
Ihe  partially calciﬁed pseudocapsule and the posterior intramural mass protruding
nto  the cystic cavity (arrow).
On histology, both the cystic wall and the small papillary projec-
ions were lined by columnar epithelia with basally located nuclei
nd clear cytoplasm; foci of mild architectural/cytological atypia
i.e. low-grade dysplasia) were also faced (Fig. 2B). The large pap-
llary fronds featured foci of high-grade dysplasia, where irregular
apillae were lined by multiple layers of cubic/columnar epithe-
ia with atypical/irregular nuclei, and prominent nucleoli (Fig. 2C).
icro-glandular nests (consistent with early stromal cancer inva-
ion) were also visible at the implant of the papillary structures. The
ub-epithelial ﬁbrous stroma was consistently hypocellular, with
o evidence of ovarian commitment (Fig. 2D). Moderate- to high-
rade inﬂammatory inﬁltrate was associated with micro-invasive
arcinoma.
Epithelial cells consistently expressed CK7, CK19, CK8/18,
onoclonal CEA, and EMA. Nuclear staining for CDX2 and apical
embrane staining for CD10 were also found, with a focal (but
harp) positivity for CK20 (Fig. 2E–G). Chromogranin, synap-
ophysin and nuclear -catenin stains were negative. Both
igh-grade dysplasia and micro-invasive cancer cells showed
onsistent immunostaining for both p53, and Ki67. Fibrous
able 1
mmunohistochemical proﬁling of the neoplasm.
Clone 
Epithelial component CK7 OV TL12/30 
CK8/18 503 
CK19 RCIT 108 
CK20 ITS20.8 
Monoclonal CEA CEA31 
EMA  E29 
CD10 56C6 
CDX2 EPR2764y 
p53  D07 
Chromogranin A DAK-A3 
Synaptophysin SY38 
Stromal component ER 6F11 
PR  LPGR312 
Smooth muscle actin (SMA) 1A4 
Vimentin V9 
a O: no expression; 1+: <30% of the cells; 2+: 30–60% of the cells; 3+: >60% of the cells.PEN  ACCESS
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(vimentin-positive) stroma featured no staining for either estro-
gen or progesterone receptors, and for smooth muscle actin
antigen (Fig. 2D) (Table 1).
A diagnosis of mucinous cystic micro-invasive carcinoma of the
pancreas (adjacent to low- and high-grade dysplasia) was ﬁnally
established (pT2 N0 M0,  stage IB; complete resection with nega-
tive histological margins [R0]). The patient recovered rapidly after
surgery and is currently (January 2013) alive, with no evidence of
disease on imaging.
3. Discussion
Turner syndrome (TS) is caused by the partial or complete lack
of a sex chromosome, which occurs in about 40–50 per 100,000
live-born girls. The spectrum of the syndrome basically results from
gene haplo-insufﬁciency on the X chromosome, which also leads to
insufﬁcient circulating levels of female sex steroids and premature
ovarian failure, associated with ovarian stroma ﬁbrosis and oocyte
degeneration.3,4
Pancreatic MCN  is a cyst-forming tumor in which mucin-
producing neoplastic epithelia coexist with ovarian-type stroma.1
The coexistence of these two  neoplastic components (epithelial-
mucinous and non-epithelial ovarian-type) is the histological
hallmark of MCN  and differentiates such tumors from IPMN,1,2
although the ovarian-type stroma is variably represented5 and may
be hypocellular/ﬁbrotic in some cases (mainly in large MCNs).1
In the present case, despite the lack of ovarian-type stroma,
several clinico-pathological features ﬁrmly support a diagnosis of
MCN  rather than IPMN: (i) the tumor occurred in the pancreatic
tail of a young (18-year-old) female; (ii) it consisted of a single
multi-locular cyst (with a calciﬁed pseudo-capsule); (iii) none of
the serial histology sections obtained from the surgical specimens
featured any communication between the cyst and the pancreatic
duct tree; (iv) the neoplastic cells consistently expressed CDX2,
CK20 and CD10 antigens. IPMNs, on the other hand, mainly affect
elderly males, they are usually located in the pancreatic head and
involve the main branches of the pancreatic ducts,6,7 and they do
not usually reveal staining for CDX2, CK20 and CD10.8,9
The occurrence of a cystic pancreatic tumor in a young female
patient also suggests the differential diagnosis with a solid-
pseudopapillary neoplasm of the pancreas (SPNP). The diagnosis
of MCN, however, was  supported by: (i) absence of solid areashyalinized/myxoid stromal bands; (ii) negative nuclear immunos-
tain for -catenin10; (iii) the absence of “regressive” features (i.e.
cholesterol crystals) coexisting with foreign-body giant cells.
Working Dilution Manufacturer Immunostaining scorea
1:200 Cell-Marque, USA 3+
1:50 Thermo Scientiﬁc, UK 3+
1:100 Bio Genex, NL 3+
1:50 Cell-Marque, USA 1+
1:400 Roche, France 2+
1:200 Thermo Scientiﬁc, UK 3+
1:20 Dako, Denmark 3+
1:100 Cell-Marque, USA 2+
1:100 Cell-Marque, USA 3+
1:100 Dako, Denmark 0
1:200 Dako, Denmark 0
1:50 Leica, UK 0
1:100 Leica, UK 0
1:100 Cell-Marque, USA 0
1:200 Cell-Marque, USA 3+
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Fig. 2. Histological and immunohistochemical features. (A) At low magniﬁcation, irregular branching papillae project into the cystic lumen. Periodic acid-Schiff stain (PAS),
original  magniﬁcation 5×. (B and C) At higher magniﬁcation, the cyst is lined with columnar/cubic epithelia with basally placed nuclei and pale cytoplasm. Cytological
atypia  ranges from low (B) to high grade (C). The implant of the neoplastic lesion shows microglandular structures consistent with stromal micro-invasion (micro-invasive
carcinoma) (C). H&E, original magniﬁcation 40×.  (D) On both morphology and immunohistochemistry, the stoma consistently lacks ovarian-type features (no estrogen
receptor  immunostaining was  documented). (E–G) Epithelial cells stain positive for both cytokeratin 19 (CK19) (E), CK20 (F) and CDX2 (G), supporting the diagnosis of MCN
rather  than IPMN.
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As for the cancer’s morphogenesis, we might speculate that the
ack of ovarian-type stroma was part of the “gonadal failure” typical
f TS. Judging from its histological features and immunohistochem-
cal proﬁling, the mesenchymal component of MCN  presumably
esults from the intra-pancreatic entrapment of ovarian stroma
n early embryogenesis. This morphogenetic hypothesis is plausi-
ly supported by: (i) the possible occurrence of neoplastic stroma
uteinization; (ii) the stromal expression of sex-cord antigens; and
iii) the elective location of MCNs within the pancreatic body/tail
proximal to the left primordial gonads).2,11
This unique case of pancreatic MCN  arising in a TS-patient raises
he question on the biological relationship between the native ovar-
an stroma and the “ovarian-type stroma” of the pancreatic MCNs.
n the present case, the consistent involvement (i.e. involution)
f the ovary stroma in both its native-ovarian and neoplastic-
ancreatic locations would support the hypothesis of pancreatic
CNs as originating from pancreatic heterotopy of ovarian tissue.
n this respect, some additional information could be potentially
chieved by comparing the phenotypes of the pancreatic with the
varian MCNs. Ovarian MCNs arising in Turner syndrome, however,
ave been only anecdotally reported and, in all these reports, the
orphology of the non-epithelial neoplastic component has been
nly shortly detailed.11–15
In conclusion, the present case of primary pancreatic MCN
rising in a TS-patient triggers some original speculation on
he morphogenesis of pancreatic MCN, also expanding the
urrent clinico-pathological knowledge of this extremely rare
ntity.
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